Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
22 nov. 2022 09h10 HE
|
Aridis Pharmaceuticals, Inc.
The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 ...